{"id":692609,"date":"2022-10-05T16:33:51","date_gmt":"2022-10-05T20:33:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/"},"modified":"2022-10-05T16:33:51","modified_gmt":"2022-10-05T20:33:51","slug":"shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/","title":{"rendered":"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">AUSTIN, TX &amp; DURHAM, NC, Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t8ZlgmOq0yu7yMKeljJbS3f8y9t6i-4Kjz5Nx3PA9TZBtSqJwKKD1plF6iQv5nTnF3L-r2c4p-hGrCq-iZsZUg==\" rel=\"nofollow noopener\" target=\"_blank\">STTK<\/a>), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC\u2019s 37<sup>th<\/sup>\u00a0Annual Meeting being held November 8<sup>th<\/sup> \u2013 12<sup>th<\/sup>, 2022, virtually and in-person in Boston.<\/p>\n<p>\n        <strong>Presentation Details<\/strong><br \/>\n        <br \/>Abstract Title: A<em>ntigen targeted butyrophilin heterodimer-based bispecific engagers induce V\u03b39\u03b42+ T cell-mediated anti-tumor activity<\/em><br \/>Abstract Number: 1203<br \/>Presenters: Suresh de Silva,\u00a0Ph.D., Vice President of Product Development at Shattuck Labs and Derek Franklin,\u00a0Ph.D., Scientist III at Shattuck Labs<br \/>Date: November 10<sup>th<\/sup><br \/>Location: Boston, MA<br \/>Poster Hall Hours: 9:00 a.m. to 9:00 p.m. ET<\/p>\n<p>Further information about the Society for Immunotherapy of Cancer Meeting can be found at:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M01ijme_DH3hOpTY5Law7jijP7a-JPbZWGZ58fEWMF-LK6ldCVqp6Rc8zcpAtUl5FOYPHJOa4mgLtfZoWyBGqtRUiNN5nUZ9LhPFj8cPYoJWjqYA8g7NWiSIKkr2j2jk\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.sitcancer.org\/2022\/home<\/a><\/p>\n<p>\n        <strong>About Shattuck Labs, Inc.<\/strong><br \/>\n        <br \/>Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck\u2019s proprietary Agonist Redirected Checkpoint, ARC<sup>\u00ae<\/sup>, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company\u2019s SL-172154 (SIRP\u03b1-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN\u2122, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q5UvkIKlmP9BkvS53qj6XgqpZwH31CzNmC0S04jiBD-ihY6-o0p9O-cu-Il4ArLFaLPDeB6QPlAhjhFmCXy_-lAhoNcmEH2iIpKguW9qQ0k=\" rel=\"nofollow noopener\" target=\"_blank\">www.ShattuckLabs.com<\/a>.<\/p>\n<p>The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.<\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>Conor Richardson<br \/>Senior Director, Finance &amp; Investor Relations<br \/>Shattuck Labs, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vqemjgQTKGCFcU0g2A8Q4Ubrtt7mhAQyK12qUPx5b7dYHY_poqW2kGOTIss_V3ViopMgG4zqSQPnREeAWIdjMzlo0bhBpHv4dW8gUpQ__AzrafOlaV1LpgHClN_eCWw0sz0V0hdEf_efneVhNP52vA==\" rel=\"nofollow noopener\" target=\"_blank\">InvestorRelations@shattucklabs.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTFlMGM1OTctNmFmZC00ZDc3LWI2M2UtNmMyMTk2NDYyZWM4LTEyMTQzODQ=\/tiny\/Shattuck-Labs-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, TX &amp; DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC\u2019s 37th\u00a0Annual Meeting being held November 8th \u2013 12th, 2022, virtually and in-person in Boston. Presentation Details Abstract Title: Antigen targeted butyrophilin heterodimer-based bispecific engagers induce V\u03b39\u03b42+ T cell-mediated anti-tumor activityAbstract Number: 1203Presenters: Suresh de Silva,\u00a0Ph.D., Vice President of Product Development at Shattuck Labs and Derek Franklin,\u00a0Ph.D., Scientist III at Shattuck LabsDate: November 10thLocation: Boston, MAPoster Hall Hours: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692609","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, TX &amp; DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC\u2019s 37th\u00a0Annual Meeting being held November 8th \u2013 12th, 2022, virtually and in-person in Boston. Presentation Details Abstract Title: Antigen targeted butyrophilin heterodimer-based bispecific engagers induce V\u03b39\u03b42+ T cell-mediated anti-tumor activityAbstract Number: 1203Presenters: Suresh de Silva,\u00a0Ph.D., Vice President of Product Development at Shattuck Labs and Derek Franklin,\u00a0Ph.D., Scientist III at Shattuck LabsDate: November 10thLocation: Boston, MAPoster Hall Hours: &hellip; Continue reading &quot;Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T20:33:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12\",\"datePublished\":\"2022-10-05T20:33:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/\"},\"wordCount\":384,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/\",\"name\":\"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=\",\"datePublished\":\"2022-10-05T20:33:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/","og_locale":"en_US","og_type":"article","og_title":"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 - Market Newsdesk","og_description":"AUSTIN, TX &amp; DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC\u2019s 37th\u00a0Annual Meeting being held November 8th \u2013 12th, 2022, virtually and in-person in Boston. Presentation Details Abstract Title: Antigen targeted butyrophilin heterodimer-based bispecific engagers induce V\u03b39\u03b42+ T cell-mediated anti-tumor activityAbstract Number: 1203Presenters: Suresh de Silva,\u00a0Ph.D., Vice President of Product Development at Shattuck Labs and Derek Franklin,\u00a0Ph.D., Scientist III at Shattuck LabsDate: November 10thLocation: Boston, MAPoster Hall Hours: &hellip; Continue reading \"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T20:33:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12","datePublished":"2022-10-05T20:33:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/"},"wordCount":384,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/","name":"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=","datePublished":"2022-10-05T20:33:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ4MyM1MTg3MDM3IzIyMDI4MzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platform-candidates-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-november-8-12\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692609"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692609\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}